Autopsy and Case Reports
http://autopsyandcasereports.org/article/doi/10.4322/acr.2018.011
Autopsy and Case Reports
Article / Clinical Case Report

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis

Joana Simões; Isabel Augusto; Sara Meireles; Lurdes Vendeira; Carlos Silva

Abstract

At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.

Keywords

Prostate cancer, Dialysis, Docetaxel, Enzalutamide, Radium-223

References

Janus N, Launay-Vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013;24(2):501-7.23038759 10.1093/annonc/mds344.

Janus N, Launay-Vacher V, Deray G, Thyss A, Thariat J. Management of chemotherapy in hemodialysis patients. Bull Cancer. 2012;99(3):371-80.22133734

Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99-114.10092957 10.2165/00003088-199936020-00002.

Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21(7):1395-403.20118214 10.1093/annonc/mdp598.

Hochegger K, Lhotta K, Mayer G, Czejka M, Hilbe W. Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer. Nephrol Dial Transplant. 2007;22(1):289-90.16935890 10.1093/ndt/gfl498.

Ito H, Inamura S, Taga M, et al. A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone. Gan To Kagaku Ryoho. 2013;40(9):1245-7.24047790

Tsang ES, de Haan M, Eigl BJ. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer. J Oncol Pharm Pract. 2017:1.28147927

Gibbons JA, Ouatas T, Krauwinkel W, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043-55.25917876 10.1007/s40262-015-0271-5.

Nguyen NC, Shah M, Appleman LJ, Parikh R, Mountz JM. Radium-223 therapy for patients with metastatic castrate-resistant prostate cancer: an update on literature with case presentation. Int J Mol Imaging. 2016;2016:1.27774318 10.1155/2016/2568031.

Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28(5):1090-7.28453701 10.1093/annonc/mdx044.

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23.23863050 10.1056/NEJMoa1213755.

Keizman D, Fosboel MO, Reichegger H, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multi- center database. Prostate Cancer Prostatic Dis. 2017;20(3):289-93.28244493 10.1038/pcan.2017.6.

 

 

 

 

 

 

 

5a996b1e0e882517081db5bf autopsy Articles
Links & Downloads

Autops Case Rep

Share this page
Page Sections